Introduction to Peptide-Based Metabolic Health Research Metabolic syndrome, obesity, insulin resistance, and type 2 diabetes represent some of the most pressing global health challenges of the 21st century. While pharmaceutical interventions have traditionally focused on single-target drugs, research peptides offer a multi-targeted approach to metabolic health, influencing appetite regulation, insulin sensitivity, fat metabolism, and energy […]
Tag Archives: Metabolic Health
Tesofensine: The Triple Reuptake Inhibitor for Weight Loss Research Tesofensine is a novel monoamine reuptake inhibitor that targets serotonin, noradrenaline, and dopamine transporters simultaneously — a “triple reuptake inhibition” mechanism that produced some of the largest weight-loss effects observed in clinical trials. It reached phase 3 development for obesity before development paused, and it remains […]
Mazdutide (GLP-1/GCGR Dual Agonist): The Next-Generation Metabolic Peptide Guide Mazdutide is a once-weekly dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR), developed for obesity and metabolic dysfunction. By combining GLP-1’s appetite suppression with glucagon’s energy expenditure effects, mazdutide represents a distinct mechanism among next-generation metabolic peptides. This guide reviews its […]
Cagrilintide: The Amylin Analog for Weight Management Research Cagrilintide is a long-acting analog of amylin, a pancreatic hormone that regulates appetite and satiety, developed for weight management and metabolic research. As the GLP-1 receptor agonist landscape expands, amylin analogs like cagrilintide represent a complementary mechanism — studied alone and in combination with semaglutide (cagrilintide 2.4mg […]
5-Amino-1MQ (NNMT Inhibitor): The Metabolic Research Compound Guide 5-Amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor that has become a major focus of metabolic and longevity research. By suppressing NNMT activity, it raises NAD+ availability and drives metabolic pathways toward fat oxidation and energy expenditure. This guide covers its mechanism, research evidence, applications, dosing, and […]
Semaglutide vs Retatrutide: Complete 2026 Comparison Guide Semaglutide and retatrutide represent two generations of incretin-based research peptides that have transformed the field of metabolic research. While semaglutide is a single-target GLP-1 receptor agonist that set the modern standard, retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This comprehensive guide compares […]
Tirzepatide Complete Research Guide: The GIP/GLP-1 Dual Agonist (2026) Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) has become one of the most studied metabolic peptides in modern pharmaceutical research. As the first dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, it represents a significant advancement […]
Retatrutide Complete Research Guide: Triple GIP/GLP-1/Glucagon Agonist (2026) Retatrutide (LY3437943) represents the next frontier in metabolic peptide research—a first-in-class triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide has demonstrated unprecedented weight loss efficacy in clinical trials, surpassing both semaglutide and tirzepatide. This comprehensive guide […]